Abstracts tagged "psoriasis and psoriatic arthritis"

Abstract Number: 1221 • 2019 ACR/ARP Annual Meeting
Impact of Psoriasis Disease Activity and Other Risk Factors on Serum-urate Levels in Patients with Psoriasis and Psoriatic Arthritis – A Post-hoc Analysis of Pooled Data from Three Phase 3-trials with Secukinumab
Mats Dehlin¹, Andreas Fasth ², Maximilian Reinhardt ³ and Lennart Jacobsson ⁴, ¹Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden, Gothenburg, Sweden, ²Medical Affairs, Novartis Sverige AB, Kista, Sweden, Stockholm, Sweden, ³Medical Affairs, Novartis Pharma GmbH, Nürnberg, Germany, Nürnberg, Germany, ⁴Dept of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden,, Gothenburg, Sweden
Background/Purpose: Increased serum uric acid (sUA), hyperuricemia, has been reported to be associated with psoriasis (1). Increased cell turnover in psoriatic skin lesions has been…
Abstract Number: 2487 • 2019 ACR/ARP Annual Meeting
Identification of Circulating MicroRNA Signatures in Patients with Psoriasis and Psoriatic Arthritis to Develop Novel Strategies for Early Diagnosis of a Bone and Joint Involvement
Judith Haschka¹, David Simon ², Sara Bayat ³, Arnd Kleyer ³, Eleni Kampylafka ³, Axel Hueber ⁴, Christian Muschitz ⁵, Susanna Skalicky ⁶, Matthias Hackl ⁶, Heinrich Resch ¹, Georg Schett ⁷, Roland Kocijan ⁸ and Jürgen Rech ⁹, ¹Karl Landsteiner Institute for Gastroenterology and Rheumatology, St. Vincent Hospital Vienna, II Medical Department, Vienna, Austria, ²Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴Sozialstiftung Bamberg, Klinikum Bamberg, Section Rheumatology, Bamberg, Germany, Bamberg, Germany, ⁵St. Vincent Hospital Vienna, II Medical Department, VINFORCE Study Group, Vienna, Austria, ⁶TAmiRNA GmbH, Vienna, Austria, Vienna, Austria, ⁷Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁸Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria, ⁹Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: MicroRNAs (miRNAs) are small non-coding RNAs which are regulating physiologic and pathological processes. In numerous diseases specific miRNA signatures have been identified and can…
Abstract Number: 993 • 2018 ACR/ARHP Annual Meeting
Elucidating the Role of the Lymphatic System in the Pathogenesis of Psoriasis and Psoriatic Arthritis
H. den Braanker^1,2, A Otten-Mus³, P Asmawidjaja⁴, N Davelaar⁵, A.A.E.A. de Smet⁶, G.P. Akkersdijk⁶, B. Fioole⁶, J.B. Jaquet⁷, A. Hofman⁸, O.P. Schuitema⁸, Sander W. Tas⁹, R. Mebius¹⁰, Erik Lubberts⁴, M.R. Kok¹¹ and R.J. Bisoendial¹¹, ¹Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ²Immunology and Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Vascular surgery, Maasstad hospital, Rotterdam, Netherlands, ⁷Maasstad hospital, Rotterdam, Netherlands, ⁸Plastic Surgery, Maasstad hospital, Rotterdam, Netherlands, ⁹Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁰Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Maasstad hospital, Rotterdam, Netherlands
Background/Purpose: Psoriasis is a common T-cell driven inflammatory skin disorder that is featured by immune cell infiltration, and vasculopathy of both blood and lymphatic vasculature.…
Abstract Number: 1391 • 2018 ACR/ARHP Annual Meeting
Patient-Acceptable Symptom State in Psoriatic Arthritis: Prevalence and Associated Factors in Real Clinical Practice
Rubén Queiro¹, Juan Cañete², Carlos Alberto Montilla-Morales³ and Miguel A. Abad⁴, ¹Rheumatology Division, HUCA, Oviedo, Spain, ²Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ³Hospital Clínico Universitario de Salamanca. Spain, Salamanca, Spain, ⁴FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are remission or low disease activity. We know little about whether these objectives correlate well with a patient-acceptable…
Abstract Number: 1588 • 2018 ACR/ARHP Annual Meeting
Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia
Julia Tan¹, J. Antonio Avina-Zubieta², Alyssa Dominique³, Hamid Tavakoli⁴ and Teresa A Simon³, ¹Medicine, University of British Columbia, Vancouver, BC, Canada, ²Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic…
Abstract Number: 1589 • 2018 ACR/ARHP Annual Meeting
Cardiac Biomarkers and Carotid Atherosclerosis and Its Progression in Psoriatic Disease
Lihi Eder¹, Vinod Chandran², Iain B. McInnes³, Richard J. Cook⁴, Dafna D Gladman⁵, Paul Welsh⁶, Naveed Sattar⁷ and Paula Harvey⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ³University of Glasgow, Glasgow, United Kingdom, ⁴Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁶nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁷Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁸Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Laboratory biomarkers indicative of cardiac ischemia or dysfunction improve cardiovascular (CV) risk stratification in the general population. Their utility in patients with psoriatic disease…
Abstract Number: 1590 • 2018 ACR/ARHP Annual Meeting
Metabolomics Profile Predicts Carotid Atherosclerosis Progression in Psoriatic Disease
Lihi Eder¹, Paula Harvey², Paul Welsh³, Vinod Chandran⁴, Iain B. McInnes⁵, Richard J. Cook⁶, Dafna D Gladman⁷ and Naveed Sattar⁸, ¹Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³nstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵University of Glasgow, Glasgow, United Kingdom, ⁶Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁷Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Metabolomic profiling of patients with psoriatic disease (PsD) offers unparalleled opportunity to unravel the molecular and clinical interactions linking PsD with cardiovascular (CV) risk.…
Abstract Number: 1615 • 2018 ACR/ARHP Annual Meeting
Comparative Risk of Atrial Fibrillation and Cardiovascular Events between TNF-Inhibitors and Ustekinumab in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Moa Lee¹, Rishi J. Desai², Yinzhu Jin³, Gregory Brill¹, Alexis Ogdie⁴ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconimics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease is a major comorbidity in patients with psoriasis (PsO) and psoriatic arthritis (PsA). Increasing evidence suggests a potential reduction in the risk…
Abstract Number: 1648 • 2018 ACR/ARHP Annual Meeting
Smoking Status in Patients with Psoriasis and Psoriatic Arthritis: An Irish Perspective
Conor Magee¹, Oliver FitzGerald², Flora Farkas¹, Natsumi Ikumi¹, Phil Gallagher³, Agnes Szentpetery⁴ and Brian Kirby⁵, ¹Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ³St. Vincent's University Hospital, Department of Rheumatology, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Dermatology, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: The BIOmarkers of COMorbidities (BIOCOM) in psoriasis study is a longitudinal study which aims to identify clinical, genetic or protein biomarker features associated with…
Abstract Number: 1866 • 2018 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Among Patients Treated with Ixekizumab: An Update on Adjudicated Data from an Integrated Database of Patients with Psoriasis and Psoriatic Arthritis
Mark C. Genovese¹, Jean-Frederic Colombel², Amanda M. Gellett³, Wen Xu³ and Dana Hardin³, ¹Department of Medicine, Stanford University, Palo Alto, CA, ²Department of Gastroenterology, The Mount Sinai Hospital, New York, NY, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Increased incidence of IBD, such as Crohn’s disease (CD) and ulcerative colitis (UC), has been observed in patients (pts) with PsA or plaque psoriasis…
Abstract Number: 2058 • 2018 ACR/ARHP Annual Meeting
Effects of Fatty Acid Supplementation in Modulation of Gut Microbiome and T-Regulatory Cells in Health and Psoriatic Disease
Fardina Malik¹, Julia Manasson¹, Alberto Herrera², Malavika Attur³, Soumya M. Reddy³, Lu Yang⁴, Sergei Koralov⁵ and Jose U. Scher¹, ¹New York University School of Medicine, New York, NY, ²New York University School of Medicine, NEW YORK, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, NY, ⁵Pathology, New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic Arthritis (PsA) affects up to 30% patients with psoriasis and is characterized by widespread synovio-entheseal inflammation. Physiologically, the human gut microbiota metabolizes dietary…
Abstract Number: 2071 • 2018 ACR/ARHP Annual Meeting
Inflammation at Distant Immunocompetent Sites Combined with a Protocol of Forced Exercise Induces Mild Joint Inflammation
Giulia Rossana Gulino¹, Margot Van Mechelen^1,2 and Rik Lories^1,2, ¹Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Belgium, ²Rheumatology, UZ Leuven, Leuven, Belgium
Background/Purpose: Psoriatic arthritis is a chronic joint disease clinically associated with psoriasis. Some patients also have signs of inflammatory bowel disease. Enthesitis, inflammation at the…
Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting
Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
Michael Gashick¹, Todd Wechter², Tessa Barrett¹, Sarah Azarchi², Stuart Katz³, Andrea L. Neimann⁴, James Krueger⁵, Sanja Jelic⁶, Edward Fisher¹, Jose U. Scher⁷ and Jeffrey S. Berger⁸, ¹Medicine/Cardiology, New York University School of Medicine, New York City, NY, ²Dermatology, New York University School of Medicine, New York City, NY, ³Medicine/Cardiology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵The Rockefeller University, New York, NY, ⁶Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, ⁷New York University School of Medicine, New York, NY, ⁸Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…
Abstract Number: 2134 • 2018 ACR/ARHP Annual Meeting
Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis
Amelia Green^1,2, Gavin Shaddick³, Rachel Charlton¹, Julia Snowball¹, Alison L Nightingale¹, Catherine Smith⁴, William Tillet^1,5 and Neil McHugh^1,5, ¹Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, ²Department of Mathematical Sciences, The University of Bath, Bath, United Kingdom, ³Centre for Data Science and Statistics, The University of Exeter, Bath, United Kingdom, ⁴Guy’s and St Thomas’ NHS Foundation Trust, St John’s Institute of Dermatology, London, United Kingdom, ⁵Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom
Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired…
Abstract Number: 2560 • 2018 ACR/ARHP Annual Meeting
Efficacy of Guselkumab in Psoriasis Patients with Self-Reported Psoriatic Arthritis with Involvement of the Scalp, Nails, Hands, and Feet: A Pooled Analysis from 2 Pivotal Phase 3 Psoriasis Studies
Ana-Maria Orbai¹, Soumya D Chakravarty², Yin You³, Shelly Kafka⁴, Chetan S Karyekar⁴ and Joseph F. Merola⁵, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Janssen Scientific Affairs, LLC/Drexel U School of Medicine, Horsham/Phila, PA, ³Janssen Research & Development, LLC, Spring House, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: VOYAGE 1 & 2 were the pivotal Ph3 GUS trials for plaque PsO.1,2 Here we compare efficacy of GUS vs PBO & adalimumab (ADA)…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].